作者
Jacob A Udell, Deepak L Bhatt, Eugene Braunwald, Matthew A Cavender, Ofri Mosenzon, Ph Gabriel Steg, Jaime A Davidson, Jose C Nicolau, Ramon Corbalan, Boaz Hirshberg, Robert Frederich, KyungAh Im, Amarachi A Umez-Eronini, Ping He, Darren K McGuire, Lawrence A Leiter, Itamar Raz, Benjamin M Scirica
发表日期
2015/4/1
期刊
Diabetes care
卷号
38
期号
4
页码范围
696-705
出版商
American Diabetes Association
简介
OBJECTIVE
The glycemic management of patients with type 2 diabetes mellitus (T2DM) and renal impairment is challenging, with few treatment options. We investigated the effect of saxagliptin in the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-Thrombolysis in Myocardial Infarction (TIMI) 53 trial according to baseline renal function.
RESEARCH DESIGN AND METHODS
Patients with T2DM at risk for cardiovascular events were stratified as having normal or mildly impaired renal function (estimated glomerular filtration rate [eGFR] >50 mL/min/1.73 m2; n = 13,916), moderate renal impairment (eGFR 30–50 mL/min/1.73 m2; n = 2,240), or severe renal impairment (eGFR <30 mL/min/1.73 m2; n = 336) and randomized to receive saxagliptin or placebo. The primary end point was cardiovascular death, myocardial infarction, or …
学术搜索中的文章
JA Udell, DL Bhatt, E Braunwald, MA Cavender… - Diabetes care, 2015